(0.11%) 5 076.27 points
(-0.15%) 38 446 points
(0.53%) 15 780 points
(-0.52%) $82.93
(-4.36%) $1.733
(-0.45%) $2 331.50
(-0.67%) $27.18
(-1.13%) $912.40
(0.09%) $0.935
(0.80%) $10.99
(0.12%) $0.804
(-0.85%) $92.40
Live Chart Being Loaded With Signals
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample...
Stats | |
---|---|
今日成交量 | 671 569 |
平均成交量 | 2.16M |
市值 | 1.14M |
EPS | $-9.91 ( 2023-11-20 ) |
下一个收益日期 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.00903 |
ATR14 | $0.149 (281.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-16 | Walsh Robert | Sell | 806 | Employee Stock option (right to buy) |
2022-11-17 | Dao-haddock Quyen Thi | Buy | 10 000 | Employee Stock Option (right to buy) |
2022-11-17 | Dao-haddock Quyen Thi | Buy | 0 | |
2022-11-17 | Dao-haddock Quyen Thi | Buy | 0 | |
2022-07-08 | Chandler Marsha Alpert | Buy | 10 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
92.34 |
Last 94 transactions |
Buy: 4 462 700 | Sell: 1 536 257 |
音量 相关性
Biocept Inc 相关性 - 货币/商品
Biocept Inc 财务报表
Annual | 2022 |
营收: | $25.86M |
毛利润: | $-2.58M (-9.99 %) |
EPS: | $-56.78 |
Q2 | 2023 |
营收: | $589 000 |
毛利润: | $-1.96M (-332.94 %) |
EPS: | $-3.50 |
Q1 | 2023 |
营收: | $673 000 |
毛利润: | $-2.36M (-349.93 %) |
EPS: | $-12.32 |
Q4 | 2022 |
营收: | $-10.29M |
毛利润: | $-14.59M (141.88 %) |
EPS: | $-32.57 |
Financial Reports:
No articles found.
Biocept Inc
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。